Brief: Xeris Biopharma Reports Q4 basic Shr Loss $0.10
08/03/2023 11:02
Mar 8 (Reuters) - Xeris Biopharma: * Q4 product revenue USD 32.539 million. * Q4 operating income USD -15.17 million * Q4 net income USD -12.93 million * Q4 basic EPS USD -0.1
Recent news on Xeris Biopharma Holdings
See all newsBrief: Xeris Biopharma Files Patent Infringement Lawsuits In US District Court - SEC Filing
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
Lundbeck expresses interest in buying Xeris, Bloomberg News reports (updated)
Xeris Biopharma rises on report of Lundbeck takeover interest